This drug is at this time the only challenge in growth for CMPS, meaning the company represents an incredibly distinctive form of pharmaceutical financial investment than ATAI."We exclude those people from our trials and we will continue on to exclude them from these therapies."Of the overall individuals in the review, 20% documented sustained enh